Vir Biotechnology (VIR) Stock
Biotech company developing immunology treatments for infectious diseases. Here's the price, business snapshot, and what's worth knowing about Vir Biotechnology in July 2026.
Vir Biotechnology, Inc. (VIR) is a small-cap biotechnology company focused on developing immunology-based therapies for infectious diseases. With a market capitalisation around $871.01M, the company is largely clinical-stage and derives value from its pipeline, research partnerships and potential licensing or product revenues if trials succeed. Investors should know Vir’s prospects depend heavily on clinical trial results, regulatory decisions and collaborations with larger partners; these events can create sharp share-price moves in either direction. The stock tends to be volatile and may have limited near-term revenue visibility until late-stage data or approvals. Strengths can include specialised scientific expertise and strategic alliances, while risks include trial failures, funding needs and competitive entrants. This summary is general educational information only and not personalised financial advice. Before investing, consider your objectives, risk tolerance and seek independent financial or tax guidance if needed.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying VIR Biotechnology's stock, expecting it to rise to $34 from $10.
Financial Health
VIR Biotechnology is making strong revenue and profits while managing costs effectively.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring VIR
Liver Disease Therapies | Next-Gen FDA Approvals
The FDA's recent accelerated approval of Gilead's Hepcludex has established the first legal treatment for a deadly liver infection known as hepatitis D. This milestone opens the door for investors to explore opportunities in companies developing innovative liver disease therapies, specialized diagnostics, and advanced patient monitoring systems.
Published: 26 May 2026
Explore BasketNext-Gen Hepatic Therapeutics | Basket Overview
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
Published: 24 May 2026
Explore BasketBiotech Patent Dispute Explained (BioNTech vs Moderna)
BioNTech is suing Moderna for patent infringement over its next-gen COVID-19 vaccine, escalating the legal rivalry between the two biotech leaders. This dispute creates a potential opening for other vaccine developers to gain a competitive edge while the giants are locked in a legal battle.
Published: 20 February 2026
Explore BasketAntiviral M&A Wave: Biotech Opportunities in 2025
Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.
Published: 16 November 2025
Explore BasketM&A Activity Overview | Pharma Biotech Investments
Merck's $9.2 billion acquisition of Cidara Therapeutics aims to bolster its antiviral portfolio ahead of the Keytruda patent expiration. This strategic purchase signals a broader investment opportunity in biotech firms with advanced clinical assets, positioning them as attractive targets for major pharmaceutical companies.
Published: 15 November 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: 11 July 2025
Explore BasketBuffett's Billions: The Philanthropy Effect
Warren Buffett just donated $6 billion to major foundations like the Gates Foundation. This curated list features companies in global health, agriculture, and education that are perfectly positioned to benefit from this massive philanthropic wave.
Published: 1 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical readouts and regulatory milestones can materially move the stock, though outcomes are uncertain and can swing valuation.
Partnership Impact
Collaborations and licensing deals can de‑risk programmes and provide funding, but commercial success is not guaranteed.
Volatile Small Cap
As a small-cap clinical company, shares can be volatile; consider time horizon and risk tolerance before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
